Hongni Jiang

Hongni Jiang


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2024 in Radiotherapy and Oncology
Verified
Journal Article
Open access
JCJinzhan Chen
Jinzhan Chen
ACAyun Chen
Ayun Chen
SYShuwen Yang
Shuwen Yang
JLJiaxin Liu
Jiaxin Liu
CXCongyi Xie
Congyi Xie
HJHongni Jiang
Hongni Jiang
We performed this systematic review and meta-analysis to investigate the performance of ML in detecting genetic mutation status in NSCLC patients. We conducted a systematic search of PubMed, Cochrane, Embase, and Web of Science up until July 2023. We discussed the genetic mutation status of EGFR, ALK, KRAS, and BRAF, as well as the mutation status at different sites of EGFR. We included a total of 128 original studies, of which 114 constructed ML models based on radiomic features mainly extracted from CT, MRI, and PET-CT data. From a genetic mutation perspective, 121 studies focused on EGFR mutation status analysis. In the validation set, for the detection of EGFR mutation status, the aggregated c-index was 0.760 (95%CI: 0.706-0.814) for clinical feature-based models, 0.772 (95%CI: 0.753-0.791) for CT-based radiomics models, 0.816 (95%CI: 0.776-0.856) for MRI-based radiomics models, and 0.750 (95%CI: 0.712-0.789) for PET-CT-based radiomics models. When combined with clinical features, the aggregated c-index was 0.807 (95%CI: 0.781-0.832) for CT-based radiomics models, 0.806 (95%CI: 0.773-0.839) for MRI-based radiomics models, and 0.822 (95%CI: 0.789-0.854) for PET-CT-based radiomics models. In the validation set, the aggregated c-indexes for radiomics-based models to detect mutation status of ALK and KRAS, as well as the mutation status at different sites of EGFR were all greater than 0.7. The use of radiomics-based methods for early discrimination of EGFR mutation status in NSCLC demonstrates relatively high accuracy. However, the influence of clinical variables cannot be overlooked in this process. In addition, future studies should also pay attention to the accuracy of radiomics in identifying mutation status of other genes in EGFR.

1 August 2025 in Journal of Thoracic Disease
Verified
Journal Article
Open access
PDF file
JCJinzhan Chen
Jinzhan Chen
ACAyun Chen
Ayun Chen
NZNing Zhang
Ning Zhang
ZCZhisheng Chen
Zhisheng Chen
JHJinxian Huang
Jinxian Huang
CXCongyi Xie
Congyi Xie
Background: Co-morbidity of chronic obstructive pulmonary disease (COPD) and type 2 diabetes mellitus (T2DM) corresponds to increasing severity and adverse clinical outcomes. This study intends to investigate the association of stress hyperglycemia ratio (SHR) with adverse outcomes in critically ill patients with COPD and T2DM. Methods: Critically ill patients diagnosed with COPD and T2DM from 2008 to 2019 were retrospectively included from the Medical Information Mart for Intensive Care IV (MIMIC-IV; version 2.2). They were assigned into three groups based on SHR tertiles, and all-cause in-hospital mortality (ACIHM) and length of intensive care unit (ICU) stay (LOIS) were the primary and secondary outcomes, respectively. The association of SHR with adverse outcomes was explored by Logistic regression, generalized linear regression, and restricted cubic spline (RCS) curve analyses, and its robustness was verified by subgroup analyses. Results: Totally 1,781 patients with COPD and T2DM were included. Logistic regression analyses revealed that after adjusting for all confounders, the risk of ACIHM increased by 51% in T3 compared with T1 [odds ratio (OR) =1.51; 95% confidence interval (CI): 1.06–2.16]. RCS curve analyses showed a statistically significant linear association between SHR and ACIHM (Pnonlinear=0.58). As shown by generalized linear regression analyses, each unit increase in SHR was associated with a 0.68-day increase in LOIS after adjusting for all confounders (β=0.68; 95% CI: 0.12–1.2). According to subgroup analyses, SHR and ACIHM had no statistically significant interaction except for the marital status subgroup (Pinteraction=0.04). Conclusions: A high SHR is associated with an increase in ACIHM and LOIS in critically ill patients with COPD and T2DM. Assessment of SHR may contribute to better risk stratification and prognostic prediction for such patients.

21 April 2025 in Health Science Reports
Verified
Journal Article
Open access
JLJianying Liu
Jianying Liu
JCJinzhan Chen
Jinzhan Chen
CXCongyi Xie
Congyi Xie
HCHaiyan Chen
Haiyan Chen
SYShuwen Yang
Shuwen Yang
YXYijiao Xu
Yijiao Xu
Background and Aims: To evaluate the efficacy and prognostic value of various immunoprognostic scoring systems—Lung Immune Prognostic Index (LIPI), modified Glasgow Prognostic Score (mGPS), and Gustave Roussy Immune Score (GRIm)—in non‐small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs).Methods: We conducted a retrospective analysis of clinical data from 219 NSCLC patients treated with ICIs at Zhongshan Hospital (Xiamen), Fudan University from June 1, 2019 to January 31, 2024. The therapeutic efficacy and predictive capabilities of the scoring systems were assessed using Kaplan–Meier curves, Cox proportional hazards models, time‐dependent ROC curves, and random survival forest models.Results: The median follow‐up was 29 months (IQR: 25.96–32.04), resulting in 93 observed deaths. Both LIPI and GRIm scores correlated with declining overall survival (OS) and progression‐free survival (PFS) as risk levels increased. LIPI demonstrated superior predictive performance at 12, 24, and 36 months (AUC: 0.70, 0.62, 0.61, respectively). Multivariate analysis identified immune‐related adverse events (irAEs) and lactate dehydrogenase (LDH) levels as independent prognostic factors for OS.Conclusion: LIPI serves as an effective prognostic tool for NSCLC patients receiving immunotherapy, outperforming individual inflammatory markers. Additionally, irAEs and LDH levels are significant independent prognostic factors for OS.

8 January 2024 in Health Science Reports
Verified
Journal Article
Open access
CCChang Cao
Chang Cao
YXYijiao Xu
Yijiao Xu
WJWeiwen Jiang
Weiwen Jiang
SWShujing Wu
Shujing Wu
YSYun Shen
Yun Shen
YYYanrong Ye
Yanrong Ye
Background and Aims: To construct a bleeding events prediction model of nonvalvular atrial fibrillation (NVAF) patients receiving rivaroxaban.Methods: We conducted a retrospective cohort study in patients with NVAF who received rivaroxaban from June 2017 to March 2019. Demographic information and clinical characteristics were obtained from the electronic medical system. Univariate analysis was used to find the primary predictive factors of bleeding events in patients receiving rivaroxaban. Multiple analysis was conducted to screen the primary independent predictive factors selected from the univariate analysis. Finally, the independent influencing factors were applied to build a prediction model by using R software; then, a nomogram was established according to the selected variables visually, and the sensitivity and specificity of the model was evaluated.Results: Twelve primary predictive factors were selected by univariate analysis from 46 variables, and multivariate analysis showed that older age, higher prothrombin time (PT) values, history of heart failure and stroke were independent risk factors of bleeding events. The area under curve (AUC) for this novel nomogram model was 0.828 (95% CI: 0.763–0.894). The mean AUC over 10‐fold stratified cross‐validation was 0.787, and subgroup analysis validation also showed a satisfied AUC. In addition, the decision curve analysis showed that the PT in combination with CHA2DS2‐VASc and HASBLED was more practical and accurate for predicting bleeding events than using CHA2DS2‐VASc and HASBLED alone.Conclusions: PT in combination with CHA2DS2‐VASc and HASBLED could be considered as a more practical and accurate method for predicting bleeding events in patients taking rivaroxaban.

3 June 2026 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
YXYiding Xu
Yiding Xu
LCLei Chen
Lei Chen
JLJie Liu
Jie Liu
QWQin Wang
Qin Wang
XZXiaodan Zhu
Xiaodan Zhu
HJHongni Jiang
Hongni Jiang
Fluconazole is key for pulmonary cryptococcosis (PC), but its hepatotoxicity (HT) risk is unclear. This study characterized fluconazole-induced liver injury in HIV-negative PC patients and explored its mechanism. We integrated clinical cohort analysis ( n = 123), network toxicology, molecular docking, and transcriptomics. HT incidence was 23.6%, predominantly cholestatic (55.2%). Immunocompromised status independently increased HT risk (aRR = 2.67, P = 0.004). Baseline ALT >16.5 U/L was the best predictor (AUC = 0.69) among liver enzymes, which showed modest discriminatory value. A model combining liver enzymes, immune status, and comedications achieved superior prediction (AUC = 0.76). Mechanistically, AKT1, ERBB2, and KDR were identified as potential core targets. Transcriptomics confirmed their significant downregulation in general cholestasis models, and molecular docking demonstrated favorable affinity binding with fluconazole (strongest for KDR: −6.5 kcal/mol). In conclusion, baseline liver enzymes and immune status are critical risk factors for fluconazole-induced HT, and fluconazole-induced cholestatic injury may involve the dysregulation of signaling pathways centered on AKT1, ERBB2, and KDR, suggesting potential targets for monitoring.

21 December 2024 in Heliyon
Verified
Journal Article
Open access
YXYijiao Xu
Yijiao Xu
LWLumin Wang
Lumin Wang
ZCZhisheng Chen
Zhisheng Chen
YHYing Huang
Ying Huang
JLJiaxin Liu
Jiaxin Liu
HJHongni Jiang
Hongni Jiang
This case report highlights the diagnostic and therapeutic complexities faced by a 56-year-old female with Good's syndrome (GS), who presented with persistent Coronavirus Disease 2019 (COVID-19) infection alongside Aspergillus spp, cytomegalovirus, and Pseudomonas aeruginosa co-infection, which collectively contributed to severe pulmonary involvement. The report further emphasizes a multifaceted treatment approach, incorporating antivirals, antifungals, antimicrobials, immunoglobulins, and antifibrotic therapy, which ultimately led to an improvement in the patient's condition. It underscored the intricate challenges of managing immunocompromised patients with multiple concurrent infections. The detailed diagnosis and treatment process of this complex case provides valuable insights to clinicians managing similar scenarios.